Frequently Asked Questions about Quince Therapeutics, Inc. (QNCX)

Name: Quince Therapeutics, Inc. (QNCX) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Quince Therapeutics, Inc. (QNCX) do?

Accepted Answer

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone frac...

Question 2

Is Quince Therapeutics, Inc. (QNCX) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of QNCX reveals an Altman Z-Score of -6.95 and a Piotroski F-Score of 2/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if QNCX fits their risk profile.

Question 3

What is the current P/E ratio for QNCX?

Accepted Answer

As of the latest trading session, Quince Therapeutics, Inc. (QNCX) has a trailing P/E ratio of -0.08.

Question 4

Who is the CEO of Quince Therapeutics, Inc.?

Accepted Answer

The current Chief Executive Officer of Quince Therapeutics, Inc. is Dirk Thye.

Question 5

What was QNCX's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Quince Therapeutics, Inc. reported annual revenues of $0.00B (2024), $0.00B (2023), $0.00B (2022), $0.00B (2021), $0.00B (2020) respectively.

Question 6

Does QNCX pay a dividend?

Accepted Answer

Quince Therapeutics, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does QNCX have?

Accepted Answer

In its latest reporting period, Quince Therapeutics, Inc. generated $-0.03B in Free Cash Flow against a total debt load of $0.01B.

Question 8

What is the Price-to-Book (P/B) ratio of Quince Therapeutics, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Quince Therapeutics, Inc. (QNCX) is currently 4.46.

Question 9

What is the Price-to-Sales (P/S) ratio of QNCX?

Accepted Answer

Based on trailing twelve-month data, Quince Therapeutics, Inc. (QNCX) trades at a Price-to-Sales (P/S) ratio of 0.00.

Question 10

What is Quince Therapeutics, Inc.'s Return on Equity (ROE)?

Accepted Answer

Quince Therapeutics, Inc. (QNCX) has a Return on Equity (ROE) of -370.46%, representing its profitability relative to shareholder equity.

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2024-12	-31.9M	4.7M	-257K	-32.2M	-36.9M
2023-12	-18.3M	5.2M	-160K	-18.5M	-23.7M
2022-12	-44M	16.6M	-133K	-44.2M	-60.8M
2021-12	-62.9M	29.9M	-180K	-63.1M	-93M
2020-12	-50.8M	14.5M	-52K	-50.9M	-65.3M

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2024-12	-31.9M	4.7M	-257K	-32.2M	-36.9M
2023-12	-18.3M	5.2M	-160K	-18.5M	-23.7M
2022-12	-44M	16.6M	-133K	-44.2M	-60.8M
2021-12	-62.9M	29.9M	-180K	-63.1M	-93M
2020-12	-50.8M	14.5M	-52K	-50.9M	-65.3M